Mental Health Key Component of President Obama's Gun Control Executive Orders
Client Alert | 1 min read | 01.22.13
On January 16, 2013, President Barack Obama issued the Gun Violence Reduction Executive Actions. Of the 23 Executive Actions, 3 in particular are particularly notable to the healthcare industry:
- No. 20 is an order to "Release a letter to state health officials clarifying the scope of mental health services that Medicaid plans must cover."
- No. 21 is an order to "Finalize regulations clarifying essential health benefits and parity requirements within ACA exchanges."
- No. 22 is an order to "commit to finalizing mental health parity regulations."
The orders can be read via the Washington Post.
President Obama also released a memo to the HHS Secretary, instructing the HHS to conduct research on the cause and possible solutions to gun violence, with a focus on the research issues with an impact on public health. Specifically, the memorandum directs HHS to begin by "identifying the most pressing research questions with the greatest potential public health impact, and by assessing existing public health interventions being implemented across the Nation to prevent gun violence." Click to read the memorandum as published in the Federal Register.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
